# 1 Exome-wide association studies discover germline mutation patterns

## 2 and identify high-risk populations in human cancers

3 Running head: Exome-wide association studies (ExWAS) in pan-cancer

4

- 5 Sipeng Shen, PhD<sup>1,2,3\*</sup>; Yunke Jiang, MS<sup>1</sup>; Guanrong Wang, MS<sup>1,4</sup>; Hongru Li, MS<sup>1</sup>;
- 6 Dongfang You, PhD<sup>1,3</sup>; Weiwei Duan, PhD<sup>6</sup>; Ruyang Zhang, PhD<sup>1,5</sup>; Yongyue Wei,
- 7 PhD<sup>1,3</sup>; Hongbing Shen<sup>2,7</sup>, PhD; Zhibin Hu, PhD<sup>2,7</sup>; David C. Christiani, MD<sup>8,9</sup>; Yang

8 Zhao,  $PhD^{1,5*}$ ; Feng Chen,  $PhD^{1,2,3*}$ 

9

- <sup>1</sup>Department of Biostatistics, Center for Global Health, School of Public Health,
- 11 Nanjing Medical University, Nanjing 211166, China
- <sup>2</sup>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu
   Collaborative Innovation Center for Cancer Personalized
   Medicine, Nanjing Medical University, 211166, Nanjing, China
- <sup>3</sup>China International Cooperation Center of Environment and Human Health, Nanjing
  Medical University
- <sup>4</sup>Department of Epidemiology, Jiangsu Health Development Research Center, Jiangsu
- 18 Province, Nanjing 210036, China
- <sup>5</sup>Key Laboratory of Biomedical Big Data of Nanjing Medical University, Nanjing
  211166, China
- <sup>6</sup>Department of Bioinformatics, School of Biomedical Engineering and Informatics,
- 22 Nanjing Medical University, Nanjing, Jiangsu 211166, China
- <sup>23</sup> <sup>7</sup>Department of Epidemiology, Center for Global Health, School of Public Health,

- 24 Nanjing Medical University, Nanjing 211166, China, Nanjing, Jiangsu 211166, China
- <sup>8</sup>Department of Environmental Health, Harvard T.H. Chan School of Public Health,
- 26 Harvard University, Boston, MA 02115, USA
- <sup>27</sup> <sup>9</sup>Pulmonary and Critical Care Division, Massachusetts General Hospital, Department
- 28 of Medicine, Harvard Medical School, Boston, MA 02114, USA
- 29

## **30 \*Send correspondence to:**

- 31 Dr. Feng Chen, SPH Building Room 412, 101 Longmian Avenue, Nanjing, Jiangsu
- 32 211166, China. Email: <u>fengchen@njmu.edu.cn</u>
- 33 Dr. Yang Zhao, SPH Building Room 404, 101 Longmian Avenue, Nanjing, Jiangsu
- 34 211166, China. Email: zhaoyang@njmu.edu.cn
- 35 Dr. Sipeng Shen, SPH Building Room 406, 101 Longmian Avenue, Nanjing, Jiangsu
- 36 211166, China. Email: <u>sshen@njmu.edu.cn</u>
- 37

#### 38 **Consent for publication**

- 39 All authors have reviewed and approved this manuscript.
- 40
- 41 **Conflicts of interest statements/Financial Disclosure statement:** The authors report
- 42 no conflicts of interest.
- 43 Funding
- This study was supported by the National Natural Science Foundation of China
  (82103946 to S.S., 82173620 to Y.Z., 81530088 to F.C.), National Key Research and
  Development Program of China (2016YFE0204900 to F.C.), Natural Science

47 Foundation of the Jiangsu Higher Education Institutions of China (21KJB330004 to

48 S.S.).

## 49 Author contributions

50 SS, YZ, and FC contributed to the study design. SS and YJ contributed to data 51 collection. SS performed statistical analyses and interpretation. SS drafted the 52 manuscript. GW, HL, DY, WD, RZ, YW, HS, ZH, and DC revised the final 53 manuscript. All authors approved the final version of the manuscript.

54

55

## 56 Abstract

57 Genome-wide association studies have discovered numerous common variants 58 associated with human cancers. However, the contribution of exome-wide rare 59 variants to cancers remains largely unexplored, especially for the protein-coding 60 variants. The UK Biobank provides detailed cancer follow-up information linked to 61 whole-exome sequencing (WES) for approximately 450,000 participants, offering an 62 unprecedented opportunity to evaluate the effect of exome variation on pan-cancer. 63 Here, we performed exome-wide association studies (ExWAS) based on single variant 64 levels and gene levels to detect their associations across 20 primary cancer types in 65 the discovery set (WES-300k, N = 284,456) and replication set (WES-150k, N =66 143,478), separately. The ExWAS detected 143 independent variants at variant-level 67 and 49 genes at gene-level, while nine variants and eight genes were shared across 68 cancers. In the cross-trait meta-analysis, we identified 239 additional independent 69 pleiotropic variants, mapping to the genes which were functional through trans-omics 70 analyses in transcriptomics and proteomics. Further, we developed exome-wide risk 71 scores (ERS) to identify high-risk populations based on rare variants with minor allele 72 frequency (MAF) < 0.05. The ERS had satisfactory performance in cancer risk 73 stratification, especially for the extremely high-risk persons (top 5% ERS) that were 74 frequently risk allele carriers. The ERS (median C-index (IQR): 0.655 (0.636-0.667)) 75 outperforms the traditional polygenic risk score (PRS) (median C-index (IQR): 0.585 76 (0.572-0.614)) for discrimination in the replication set. Our findings offer further 77 insight into the genetic architecture of human exomes for cancer susceptibility.

78 Keywords: exome-wide association studies, pan-cancer, rare variants, polygenic risk
79 score, cross-trait

80

# 81 Introduction

Cancer ranks as a leading cause of death and a critical barrier to increasing life expectancy worldwide <sup>1</sup>. Population-based early screening approaches showed a remarkable reduction in cancer mortality <sup>2</sup>, such as low-dose computed tomography (CT) screening for lung cancer <sup>3,4</sup>. Considering the cost-effectiveness balance, it is generally agreed that screening should be limited to the high-risk population. However, precisely identifying high-risk persons is still challenging, while cancer is a complex disease that derives from environmental exposure and inherent heredity <sup>5</sup>.

89 Cancer shows substantial heritability from genetic variants <sup>6</sup>. Genome-wide 90 association studies (GWAS) have identified numerous associations of genome-wide significance between genetic variants and common diseases <sup>7</sup>. However, common 91 single nucleotide polymorphisms (SNPs) identified in GWAS explain only a small 92 93 fraction of heritability, which might be limited to the coverage of SNP arrays<sup>8</sup>. 94 Exome-wide association studies (ExWAS) have shown that rare coding variants tend 95 to have larger phenotypic effects than common SNPs and contribute an essential component of heritability<sup>9</sup>. Due to the effect allele frequency being generally low in 96 97 ExWAS, the sample size should be large (e.g., n > 100,000) to guarantee the statistical power, especially for the rare variants  $^{10,11}$ . 98

Moreover, it is widely recognized that the polygenic risk score (PRS) is a powerful tool to discriminate the high-risk population susceptible to specific cancer <sup>12,13</sup>. However, most PRSs are generated using common variants derived from the SNP array, which ignore the rare variants with larger effects, especially those located on exomes with remarkable biological significance <sup>14,15</sup>. Thus, the rare variants might provide complementarity value for cancer risk stratification based on traditional PRS.

105 The UK Biobank (UKB) is a powerful resource for evaluating the associations 106 between coding variants and human diseases because of its large sample size with

high-quality whole-exome sequencing (WES) data ( $n \approx 450,000$ ) <sup>16,17</sup>. In our study, we investigated the landscape of genetic variants with multiple primary cancers through UKB WES project. Further, we leveraged the rare variants to improve the risk stratification models to identify the high-risk population.

111

## 112 **Results**

## 113 Exome-wide association study for single variants

114 Our study included the whole-exome sequencing 450k (WES-450k in data-field 115 23148) population of European ancestry in UK Biobank (Table S1). To ensure the 116 robustness of the results, we conducted a two-stage association study in two separate 117 datasets: discovery set (interim WES-300k in data-field 23146, N = 284,456) and 118 replication set (the remaining WES-150k, N = 143.478). Overall, our study included 119 20 cancer types containing 106,836 primary cancer cases and 321,098 shared 120 cancer-free controls. The number of cancer cases ranged from 773 (thyroid cancer) to 121 32,307 (skin cancer). 1,769,329 exome single nucleotide variants (SNVs) annotated 122 putative loss-of-function (LoF), missense, and synonymous passed the quality control 123 procedures.

For single-variant analyses, 306,031 variants with minor allele count (MAC) $\geq$ 10 were tested in ExWAS. The genomic inflation factor (GIF) values suggested no obvious population stratification (Figure S1). When combining all the *P* values of pan-cancer, the GIF was 1.105, indicating the existing pleiotropic effects (Figure S2).

Among the 20 cancer types, ExWAS detected 255 signals from 242 variants that passed the genome-wide significance level ( $P < 5 \times 10^{-8}$ ) in 12 cancer types. After LD pruning, we observed 153 independent signals across 64 chromosome regions

131 (LD- $r^2 < 0.5$ ) (Figure 1a, Table S2). The top variant with maximum association signals 132 was rs555607708 (22:28695868:AG:A, frameshift variant of CHEK2, HGVSp: 133 p.Thr367fs, effect allele frequency: 0.22%), which was associated with three cancer types including breast [OR (95% CI): 4.15 (3.16-5.43),  $P = 7.24 \times 10^{-25}$ ], prostate [OR 134 (95% CI): 2.40 (1.82-3.16),  $P = 3.48 \times 10^{-10}$ ] and leukemia [OR (95% CI): 8.48 135  $(4.12-17.48), P = 1.21 \times 10^{-9}$ ]. 136 137 Additionally, eight independent variants had significant associations with at least two 138 cancer types, leading by rs6998061 (OR=0.82~0.89, missense variant in POU5F1B), 139 rs16891982 (OR=1.42~1.46, missense variant in *SLC45A2*), rs387907272 140 (beta=24.1~76.2, LoF variant in MYD88), rs3787220 (OR=0.85~0.88, synonymous 141 variant in NCOA6), rs77681059 (OR=1.11~1.32, missense variant in TUBB3), 142 rs1805007 (OR=1.34~1.64, missense variant in MC1R), rs56288641 (OR=1.28~1.59, 143 missense variant in VPS9D1), rs1126809 (OR=1.13~1.23, missense variant in TYR). 144 More than half of the variants were shared between skin cancer and melanoma, 145 including three variants located on 16q24.3. The remaining three variants were shared 146 among breast, prostate, leukemia, colorectal cancers, and non-Hodgkin's lymphoma 147 (NHL) (Table S3).

## 148 *Exome-wide association study based on gene-level*

149 In addition to the variant-level analyses, we performed gene-based association studies 150 to capture the effects of ultra-rare variants. We used different genetic models to detect 151 the signals, according to minor allele frequency threshold (0.05, 0.01, 0.001) and 152 variant functional annotation (LoF, LoF+missense, LoF+missense+synonymous). After Bonferroni correction, 49 genes were considered significant ( $P < 2.5 \times 10^{-6}$ ) 153 154 (Figure 1b, Table S4). The top genes with the highest hit frequency were CHEK2 [breast (OR = 1.03,  $P = 1.08 \times 10^{-22}$ ), prostate (OR = 1.02,  $P = 1.28 \times 10^{-12}$ ), leukemia 155  $(OR = 1.04, P = 1.55 \times 10^{-13})$ ], BRCA2 [breast (OR = 1.08, P = 1.43 \times 10^{-38}), ovary (OR 156

157 = 1.14,  $P = 1.94 \times 10^{-30}$ , prostate (OR = 1.04,  $P = 5.98 \times 10^{-8}$ )], and ATM [breast (OR =

158 1.10,  $P = 4.33 \times 10^{-10}$ , prostate (OR = 1.04,  $P = 1.89 \times 10^{-9}$ ), pancreas (OR = 1.04, P =

159  $2.67 \times 10^{-7}$ )], which were associated with three cancer types. VPS9D1, SLC45A2,

160 *BRCA1, MSH6*, and *MC1R* were associated with two cancer types (Table S5).

We summarized the association results of genes that reached significance level in at least two cancer types from variant-level and gene-level analyses (Figure 1c). Four genes, including *CHEK2*, *ATM*, and *BRCA1/2*, showed a close relationship with human cancers.

#### 165 Shared genetic cross-trait meta-analyses identify pleiotropic signals

To identify additional potential pleiotropic variants associated with multiple cancers, we performed a cross-trait meta-analysis using Association analysis based on SubSETs (ASSET). 1,572 variants that reached  $P < 10^{-4}$  in any cancer type were included. We identified 150 independent variants (mapping to 86 genes, 43 chromosome cytobands) with significant one-directional effects (Table S6) and 89 independent variants (mapping to 38 genes, 16 cytobands) with significant bidirectional effects (Table S7) (Figure 2a).

We checked the pleiotropic variants in NHGRI-EBI GWAS Catalog <sup>18</sup>, a publicly available database that collected all published GWAS signals phenome-wide. The due date of associations collection was April 7, 2022. More than half of the identified variants were not reported in GWAS Catalog [100 novel one-directional variants (66.7% of all), 59 novel bidirectional variants (66.3% of all)] (Table S6-S7).

We also summarized the shared genetic variants across cancers identified in ASSET subgroups according to their effect direction (Figure 2b). The top cancer pairs with the highest shared one-directional variants were skin & melanoma (79 variants), skin & thyroid (69 variants), sarcoma & skin (51 variants), NHL & skin (50 variants), esophagus & skin (47 variants). The top cancer pairs with the highest heterogeneous

bidirectional variants were leukemia & thyroid (51 variants), liver & thyroid (50 variants), lung & sarcoma (48 variants), skin & liver (48 variants), lung & thyroid (48 variants) (Table S8).

#### 186 Trans-omics functional analysis for the identified genes

187 We performed a trans-omics analysis to integrate the identified genes from single 188 variant, gene based and cross-trait meta-analyses into transcriptomics and proteomics. 189 Gene expression was obtained from the recompute transcriptomic data of The Cancer 190 Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx). 98 unique 191 protein-coding genes across 15 tissue types that passed quality control were included. 192 Through comparisons of gene expression in tumor and healthy normal tissues, we 193 observed remarkable differences in gene expression. The well-known HLA family 194 genes, BRCA1/2, CHEK2, and TUBB3 were up-regulated in tumor tissues, while ATM, 195 VPS9D1, and MC1R were down-regulated. However, some genes showed 196 heterogenous trends across cancers, such as the KRT family, POU5F1B, and TET2 197 (Figure 3a, 3b).

Further, we performed a KEGG pathway enrichment analysis for the identified genes. Numerous immune-related pathways were identified, such as Th1 and Th2 cell differentiation ( $P = 1.46 \times 10^{-3}$ ), Th17 cell differentiation ( $P = 2.63 \times 10^{-3}$ ), and inflammatory bowel disease ( $P = 3.94 \times 10^{-4}$ ), as well as the classical cancer-related pathways, including cell adhesion molecules ( $P = 1.29 \times 10^{-5}$ ), platinum drug resistance ( $P = 6.14 \times 10^{-4}$ ), p53 signaling pathway ( $P = 6.14 \times 10^{-4}$ ), and NF-kappa B signaling pathway (P = 0.018) (Figure 3e, Table S9).

205 Proteomic data were collected across ten tissue types from The National Cancer 206 Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC). We observed 207 moderate differences by comparing protein abundance in tumor and adjacent normal

tissues. Interestingly, some proteins showed similar patterns with the corresponding
gene expression, such as *HLA* family genes and *CHEK2*. However, a reverse trend
was also found for some genes. For example, *BRCA2* was down-regulated in
proteomics of tumor tissues (Figure 3c, 3d).

212 Using the STRING database to integrate all known and predicted proteins-protein

- 213 interactions, we identified two large clusters: one was related to the HLA (e.g., HLA
- family genes, MICA, BTNL2) and immune function (e.g., CTLA4, CTSS, SAMHD1);
- another was related to DNA damage response and repair (e.g., BRCA2, ATM, CHEK2,

216 MSH6) (Figure 3f). In addition, three small clusters were also identified, including the

217 keratin family, BPI fold containing family B, and melanogenesis.

#### 218 Identify high-risk population based on rare variants

219 We developed exome-wide risk scores (ERS) to identify high-risk population based 220 on rare variants with minor allele frequency (MAF) < 0.05 for incident cancers. The 221 discovery set (WES-300k population) was used for risk score training, while the 222 replication set (WES-150k) was used for external validation. After screening using the 223 least absolute shrinkage and selection operator (LASSO) with 10-fold cross-validation, 224 we included a moderate number of rare variants in ERS (median [interquartile range 225 (IQR)]: 103 (82-199)), ranging from 39 variants (thyroid) to 585 variants (skin) 226 (Table S10).

We performed a risk stratification analysis to identify the high-risk populations susceptible to specific cancer types. We defined three risk levels: extremely high-risk (top 5% ERS), high-risk (5%-25% ERS), and low-risk (bottom 75% ERS), which might be applicable to different medical screening strategies. The ERS could stratify the cancer absolute incidence risk significantly in the replication set (Figure 4) and the whole UKB-450k population (Figure S4) (all log-rank  $P < 2.2 \times 10^{-16}$ ). Using the low-risk population as the reference, the extremely high-risk persons had hazard ratios

234 (HRs) ranging from 4.52 to 9.92 [median (IQR): 7.20 (6.44-7.85)], which 235 outperformed PRS [HR median (IQR): 2.44 (1.95-2.80)]. The high-risk persons had 236 HRs ranging from 1.37 to 4.43 [median (IQR): 1.97 (1.75-2.33)), while the PRS had 237 HRs ranging from 1.11 to 2.15 with median (IQR): 1.56 (1.41-1.79) (Figure 5a, 5b). 238 Thus, the ERS had satisfactory performance in cancer risk stratification, especially for 239 the extremely high-risk persons that were frequently risk allele carriers. The 240 distributions of ERS in each cancer type were shown in Figure S5. Most people did 241 not carry the causal alleles, while only a few were high-risk carriers. The density plot 242 of cases and controls indicated the cancer cases had obvious larger ERS than controls 243 (Figure S6).

Further, we evaluated the discrimination abilities of ERS and PRS using the C-index for ten-year cancer incidence. The C-index values in the replication set were stable, ranging from 0.601 to 0.686 [median (IQR): 0.655 (0.636-0.667)], outperforming the traditional PRS [median (IQR): 0.585 (0.572-0.614)] (Figure 5c). Through Spearman correlation analysis, we found low correlation between ERS and PRS (average  $r_s =$ 0.016), indicating the complementary predictive value for the rare exome variants (Table S11).

251

#### 252 Methods

## 253 Study population and phenotype definition

The UK Biobank (UKB) is a population-based prospective cohort of individuals aged 40–69 years, enrolled between 2006 and 2010. The work described herein was approved by the UK Biobank under application no. 83445. All the phenotype data were accessed in March 2022.

258 Health-related outcomes were ascertained via individual record linkage to national

259 cancer and mortality registries and hospital in-patient encounters. Cancer diagnoses 260 were coded by International Classification of Diseases version 10 (ICD-10) codes. 261 Individuals with at least one recorded incident diagnosis of a borderline, in situ, or 262 primary malignant cancer were defined as cases collected from data fields 41270 263 (Diagnoses - ICD10), 41202 (Diagnoses - main ICD10), 40006 (Type of cancer: 264 ICD10), and 40001 (primary cause of death: ICD10). Finally, we analyzed 20 primary 265 cancer types with overall cases > 500, including bladder, brain, breast, colorectal, 266 esophagus, head and neck, kidney, lung, leukemia, liver, non-Hodgkin's lymphoma 267 (NHL), ovary, pancreas, prostate, sarcoma, melanoma, skin (non-melanoma), stomach, 268 thyroid, uterus cancers.

To ensure the robustness of the results and validate the risk stratification model, we used the WES-300k population released on Sep 28<sup>th</sup> 2021 as the discovery set and the remaining WES-150k population additionally released on Oct 29<sup>th</sup> 2021 as the replication set. We included only participants of European ancestry. The demographic and cancer characteristics were described in Table S1. All the data analyses were performed on DNAnexus Research Analysis Platform (RAP).

#### 275 Quality control for the genetic variants

276 Whole-exome sequencing data for UKB participants were generated using the IDT 277 xGen v1 capture kit on the NovaSeq6000 platform. The UK Biobank WES 450k 278 release includes CRAM and gVCF files processed using the OQFE protocol<sup>19</sup>. 279 Single-sample variants were called from OQFE CRAMs with DeepVariant 0.0.10 280 employing a retrained model and are provided as single-sample gVCFs. All gVCFs 281 were aggregated with GLnexus 1.2.6 using the default joint-genotyping parameters 282 for DeepVariant. The OQFE protocol maps to a full GRCh38 reference version 283 including all alternative contigs in an alt-aware manner. Genotype depth filters (SNV 284  $DP \ge 7$ , indel  $DP \ge 10$ ) were applied prior to variant site filters requiring at least one

variant genotype passing an allele balance filter (heterozygous SNV AB>0.15,
heterozygous indel<0.20). The detailed parameters were described in Category 170 of</li>
the UKB showcase. In addition, we filtered out the variants with low allele counts if a
variant had minor allele count (MAC) < 3 in the discovery set or MAC < 2 in the</li>
replication set.

## 290 Exome-wide association for single variants and gene levels

291 Single-variant and gene-based association analyses were performed using SAIGE 292 v1.0.5<sup>20,21</sup>. SAIGE is a toolkit developed for genome-wide association tests in 293 biobank level datasets, which uses saddlepoint approximation to handle extremely 294 case-control imbalance of binary traits and linear mixed models to account for sample 295 relatedness. The variant-level association tests included high-quality and reliable 296 variants with MAC≥10. The exact inclusion criteria for single variants were: (i) MAC 297  $\geq$ 3 in both cases and controls in the discovery set; (ii) MAC $\geq$ 2 in both cases and 298 controls in the replication set. The variants were functionally annotated using Variant 299 Effect Predictor (VEP) software <sup>22</sup>. In addition to the coding variants that alter protein 300 sequences, synonymous variants could also disturb the level of mRNA expression and have non-neutral functions <sup>23,24</sup>. Thus, variants annotated as putative loss-of-function 301 302 (LoF, including nonsense, splice site, and frameshift variants), missense, and 303 synonymous were included in the analysis. Independent variants were pruned out 304 using the PLINK v1.9 clump function (--clump-r2 0.50 --clump-kb 500).

For gene-based analysis, we included rare and ultra-rare variants with minor allele frequency (MAF) < 0.05, 0.01, or 0.001. Three genetic models were considered: LoF, LoF+missense, LoF+missense+synonymous. Of all the combinations, we reported the association results with the lowest *P* value to collectively capture a wide range of genetic architectures <sup>25</sup>. The effect sizes and 95% confidence interval (CI) of genes were estimated by burden tests.

In all the association analyses, we adjusted the covariates including age, gender (excluding sex-specific tumors), Body Mass Index (BMI), smoking status (binary), drinking status (binary), and the top 10 principal components (PCs). Meta-analysis was used to summarized the results between discovery and replication sets for single variants by METAL software <sup>26</sup>. At the same time, the gene-based *P* values were aggregated by aggregated Cauchy association test (ACAT) method <sup>27</sup>.

We reported the significant associations when the variants/genes meet the following criteria: (i) P < 0.05 in both discovery and replication sets; (ii) reach genome-wide significant level ( $P < 5 \times 10^{-8}$ ) in the meta-analysis for variant-level or pass Bonferroni correction threshold  $P < 2.5 \times 10^{-6}$  (nearly 20,000 protein-coding genes tested) for gene-level.

#### 322 Shared genetics analyses to identify potential genes across cancers

323 To discover more potential variants associated with multiple cancers, we applied a 324 cross-trait meta-analysis using Association analysis based on SubSETs (ASSET) <sup>28</sup>. 325 ASSET is a statistical tool specifically designed to be powerful for pooling 326 association signals across multiple cancers when true effects may exist only in a 327 subset of the cancers. We considered both one-sided (one-directional) and two-sided (bidirectional) ASSET. Variants with association  $P < 1 \times 10^{-4}$  in any cancer type were 328 included. Variants were considered significant while reaching  $P_{\text{overall}} < 5 \times 10^{-8}$  and P <329 330 0.05 for each side in bidirectional tests.

#### 331 Comparison analyses for gene expression in tumor and healthy normal tissues

The UCSC Toil Recompute Compendium provides processed transcript-level
RNA-Seq data from TCGA tumor tissues and GTEx healthy normal tissues quantified
using a unified computational pipeline to remove computational batch effects. We

used this data to perform comparative analysis across tumor and health normal tissues from both projects <sup>29</sup>. All the gene expression values were normalized to transcripts per million (TPM) and then logarithmically transformed. After filtering, 15 tissue types with sample size > 100, including 7,085 TCGA tumor tissues and 4,311 GTEx normal tissues, were analyzed (Table S12). We used Student's t-test ( $P_{bonferroni} < 0.05$ ) and fold change (FC>1.5 or FC<0.5) to identify the differential gene expression between tumor and healthy normal tissues.

#### 342 Pathway enrichment analysis

We collected the pathway information with gene sets from the KEGG database, containing a total of 186 pathways up to March 2022. All enrichment analyses were performed using the R package *clusterProfiler* <sup>30</sup>.

#### 346 Comparison analyses for protein abundance in tumor and adjacent normal tissues

The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis <sup>31</sup>. Eleven cancer types with available protein abundance data of 1,270 tumor tissues and 845 adjacent normal tissues were collected from ten tissue types (Table S13). The differential proteins were identified following the same criteria with gene expression.

#### 353 Protein-protein interaction analysis

To further understand the protein-protein interactions, we used the STRING database, which considered both physical interactions as well as functional associations <sup>32</sup>. The protein interaction network was clustered into different colors using Markov Clustering (MCL).

#### 358 Polygenic risk score generation

359 The polygenic risk score (PRS) aggregates the effects of numerous genetic variants 360 into a single number which predicts genetic predisposition for a phenotype. To 361 investigate the association of PRS with cancer risk, we generated the PRS based on 362 previous literature reports. The SNP information and score weights were collected from the PGS Catalog database <sup>33</sup>. PGS Catalog is an open database of published 363 364 PRSs, covering >2,000 scores for various phenotypes. If multiple PRSs were reported 365 for one cancer, we selected the one generated from the largest sample size. After 366 filtering, 17 PRSs were collected and generated in UKB imputed genotype population 367 (data field 22828: Imputation from genotype), except for liver, stomach, and sarcoma 368 cancers that did not have reported PRSs (Table S14).

#### 369 Development and validation of the risk stratification models based on rare variants

We developed an exome-wide risk score (ERS) for population risk stratification based on rare variants (MAF<0.05) for each cancer separately. The analyses were restricted to incident cancers. To perform independent training and validation phases, the selected variants and weights were determined using the association information in the discovery set.

We select the rare genetic variants reaching  $P < 1 \times 10^{-4}$  in the discovery set as the first step. The variants identified in this analysis were further screened through penalized regression using the least absolute shrinkage and selection operator (LASSO) after 10-fold cross-validation to reduce the overfitting and collinearity problem. When high correlation exists, variants representing independent loci with the strongest statistical significance were retained. The ERS was generated as:  $ERS = \sum_{1}^{n} \beta_{i}G_{i}$ , where  $\beta_{i}$ 

denoted the coefficient of the i<sup>th</sup> variant  $G_i$  calculated by SAIGE in the discovery

382 set.

In the validation phase, the variant panel with previously determined weights wasused to generate ERS in the replication set.

385 We used person-year to describe the absolute cancer incidence risk, which was 386 defined as the time gap from the date of cohort enrollment to cancer diagnosis or the 387 last follow-up, whichever came first. Hazard ratios (HRs) and 95% confidence 388 interval (CI) were used to evaluate the association between ERS and cancer risk based 389 on Cox proportional hazards models, adjusting for age, sex (excluding sex-specific 390 cancer), and top ten principal components. We compared effect sizes of ERS for 391 cancer risk based on the top 5% (extremely high-risk), 5~25% (high-risk), and bottom 392 75% (low-risk) percentile of ERS. The discrimination performance of the risk scores 393 were evaluated by Harrell's C-index.

394

395

#### 396 **Discussion**

397 In this study, we comprehensively evaluated the susceptibility between genetic 398 variants on human exome and 20 primary cancer types in approximately 420,000 399 UKB participants of European ancestry. To our knowledge, this is the first 400 exome-wide pan-cancer study including almost the whole UKB population, which 401 could improve the statistical power compared with some previous studies using the early-phase UKB 200k population <sup>34,35</sup>. Trans-omics analyses were performed to 402 403 evaluate the functional evidence of identified signals, including genomics, 404 transcriptomics, and proteomics. Moreover, through establishing the independent 405 discovery and replication sets, the signals identified and the risk stratification models 406 could be validated externally to ensure their robustness, especially for the rare 407 variants with smaller MAF.

408 Our first major finding discovers exome-wide signals associated with multiple cancers. 409 In the ExWAS analyses, the identified protein-coding variants in CHEK2 (known as 410 c.1100del), BRCA1/2, ATM have been reported associated with cancers in previous 411 studies <sup>36</sup>. Based on such a large-scale population, novel variants and genes were also 412 identified. For example, the missense variant rs6998061 in POU5F1B, which was 413 predicted as a possibly damaging SNV by VEP, was associated with prostate and 414 colorectal cancers. POU5F1B was a protein-coding gene highly homologous to OCT4 415 <sup>37</sup>, which was recently shown to be transcribed in cancer cells. It has been found 416 related to tumorigenicity and tumor growth in vivo and could promote angiogenesis 417 and cell proliferation and inhibits apoptosis in cancer cells <sup>38</sup>. The stop lost variant 418 rs387907272, predicted as probably damaging in MYD88, was associated with 419 leukemia and NHL. MYD88 encodes a cytosolic adapter protein that plays a central role in the innate and adaptive immune response <sup>39</sup>. It functions as an essential signal 420 421 transducer in the interleukin-1 and Toll-like receptor signaling pathways<sup>40</sup>. Moreover, 422 mutations in *MYD*88 could activate NF- $\kappa$ B and its associated signaling pathways, thereby promoting B-cell proliferation and survival <sup>41</sup>. Thus, this germline mutation 423 424 might be a promising target for clinical implications. Moreover, we identified multiple 425 SNVs located in 16q24.3 that were shared between skin cancer and melanoma, 426 including VPS9D1, MC1R, and TUBB3. VPS9D1, a protein-coding gene that affects 427 protein binding activity, was significantly associated with skin cancer and melanoma. 428 Although its role in cancer has not been reported, its antisense VPS9D1-AS1 could 429 promote tumorigenesis and progression by mediating micro RNAs via the Wnt/ $\beta$ -catenin signaling pathway in multiple cancers <sup>42,43</sup>. Human *MC1R* has an 430 431 inefficient poly(A) site allowing intergenic splicing with its downstream neighbor 432 TUBB3, which were involved in melanogenesis. Melanogenesis is a key parameter of 433 differentiation in melanocytes and melanoma cells that could affect the treatment of pigmentary disorders <sup>44</sup>. Therefore, the SNVs and genes we identified had remarkable 434 435 biological functions that were practical for precise clinical implications.

436 Our second major finding identified the pleiotropic variants shared among cancers. 437 We observed strong functional evidence for the identified genes from KEGG pathway 438 network and protein-protein interaction network through trans-omics analyses for 439 gene expression and protein abundance. We found several essential function modules 440 from proteomics. The DNA damage response and repair agents are widely used in 441 clinical oncology given the expanding role of immune checkpoint blockade as a 442 therapeutic strategy <sup>45</sup>. The HLA locus, located on chromosome 6, is among the most polymorphic regions of the human genome <sup>46</sup>. HLA dysfunction is deeply involved in 443 444 the immune evasion events in the development and progression of certain cancers <sup>47</sup>. 445 A previous study has reported that somatic mutation in HLA was associated with multiple cancers <sup>48</sup>; we hereby demonstrated that germline mutation in HLA was also 446 447 relevant. In addition, the keratin family and BPI fold containing family B (BPIFB) were also related to cancers that had certain biological functions <sup>49,50</sup>. 448

449 Our third major finding improves the ability for high-risk population identification. It 450 is widely recognized that early screening for cancers is most likely beneficial when 451 the target tumor type has relatively uniform biology and a slower rate of progression  $^2$ . 452 Targeting on high-risk populations with appropriate strategies for early detection could get remarkable benefits of mortality reduction <sup>51-53</sup>. However, the selection of 453 454 individual to be screened is a complex procedure, with difficulty accurately 455 identifying high-risk persons who are most likely to benefit from screening. Because 456 cancer is heritable, PRS is emerging as the quantitative measurement for individual 457 genetic risk. However, the heritability for common variants identified in GWAS is 458 limited, while the contribution of rare variants could not be ignored. Therefore, we 459 leveraged the rare variants to construct the ERS to offset this limitation. By evaluating 460 C-index and risk stratification, we demonstrated the added values of rare variants.

461 ERS could be combined with specific tumor screening strategies, suggesting that 462 people with extremely high risk should be screened frequently (e.g., once a year), and

those with high risk should be screened regularly (e.g., once every three years), which
is expected to further reduce the cancer mortality. Therefore, ERS is expected to serve
as an informative benchmark to incorporate the PRS and baseline information that
have been used in cancer risk assessment.

467 Our work has several strengths. First, we comprehensively evaluated the exome-wide 468 genetic variants in 20 cancer types on variant and gene levels among 420k 469 participants and analyzed the cross-cancer pleiotropy through cross-trait meta-analysis. 470 Second, we explored the relationship between identified genes and cancers at 471 multi-omics levels, including genomics, transcriptomics, and proteomics. The 472 trans-omics analyses revealed that the identified signals were functional. Third, we 473 focused on the high-risk population identification based on exome-wide variants, 474 while few studies developed risk scores using rare variants. We demonstrated the 475 stable performance of ERS across pan-cancer in the replication set, especially for its 476 ability to identify the extremely high-risk persons. Therefore, the ERS might serve as 477 a complementary genetic risk assessment tool combined with the existing screening 478 guidelines.

479 It is essential to acknowledge the limitations of our study. First, this study was 480 conducted in the UKB population only. Although we established a discovery set and 481 replication set, it is not strictly independent validation. Therefore, future large-scale 482 population studies should be conducted to replicate these findings. Second, we 483 focused on individuals of European ancestry only. Moreover, it is essential to evaluate 484 the associations of variants and performance of ERS in non-European populations. 485 Third, we mainly investigated the genetic effects of population risk stratification. 486 However, the contribution of environmental factors should not be ignored. 487 Well-established risk models incorporated with environmental factors, PRS, and ERS 488 should be developed for specific cancer.

489 In conclusion, our study provides novel insights into human exomes and rare variants

- 490 through comprehensive analyses of genetic susceptibility to human cancers and
- 491 subsequent target analyses on specific genes and risk stratification.
- 492

#### 493 Data Availability

- 494 UK Biobank data is available from https://www.ukbiobank.ac.uk/. TCGA data is
- 495 available from https://portal.gdc.cancer.gov/. GTEx data is available from
- 496 https://www.gtexportal.org/home/. CPTAC data is available from
- 497 https://pdc.esacinc.com/pdc/pdc.

## 498 Code Availability

- 499 The R software codes that support our findings are available from the corresponding
- 500 author by a reasonable request.
- 501

502

# 503 **Reference**

504 1 Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of 505 Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a 506 cancer journal for clinicians 71, 209-249, doi:10.3322/caac.21660 (2021). 507 2 Shieh, Y. et al. Population-based screening for cancer: hope and hype. Nat Rev 508 *Clin Oncol* **13**, 550-565, doi:10.1038/nrclinonc.2016.50 (2016). 509 Li, N. et al. One-off low-dose CT for lung cancer screening in China: a 3 510 population-based, prospective cohort study. The Lancet. multicentre, 511 Respiratory medicine 10, 378-391, doi:10.1016/S2213-2600(21)00560-9 512 (2022).513 4 Kovalchik, S. A. et al. Targeting of low-dose CT screening according to the 514 death. Ν risk of lung-cancer Engl JMed 369, 245-254, 515 doi:10.1056/NEJMoa1301851 (2013). 516 5 Lichtenstein, P. et al. Environmental and heritable factors in the causation of 517 cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N 518 Engl J Med 343, 78-85, doi:10.1056/NEJM200007133430201 (2000). 519 6 Rashkin, S. R. et al. Pan-cancer study detects genetic risk variants and shared 520 basis in two large cohorts. genetic Nat Commun 11. 4423. 521 doi:10.1038/s41467-020-18246-6 (2020). 522 7 Visscher, P. M., Yengo, L., Cox, N. J. & Wray, N. R. Discovery and 523 implications of polygenicity of common diseases. Science 373, 1468-1473, 524 doi:10.1126/science.abi8206 (2021). 525 8 Tam, V. et al. Benefits and limitations of genome-wide association studies. 526 Nature reviews. Genetics 20, 467-484, doi:10.1038/s41576-019-0127-1 527 (2019). 528 9 Barton, A. R., Sherman, M. A., Mukamel, R. E. & Loh, P. R. Whole-exome 529 imputation within UK Biobank powers rare coding variant association and 530 53. 1260-1269, fine-mapping analyses. Nat Genet 531 doi:10.1038/s41588-021-00892-1 (2021). 532 Van Hout, C. V. et al. Exome sequencing and characterization of 49,960 10 533 individuals in the UK Biobank. Nature 586, 749-756, 534 doi:10.1038/s41586-020-2853-0 (2020). 535 Cirulli, E. T. et al. Genome-wide rare variant analysis for thousands of 11 536 phenotypes in over 70,000 exomes from two cohorts. Nat Commun 11, 542, 537 doi:10.1038/s41467-020-14288-y (2020).

538 539	12	Lewis, C. M. & Vassos, E. Polygenic risk scores: from research tools to clinical instruments. <i>Genome medicine</i> <b>12</b> , 44,
540		doi:10.1186/s13073-020-00742-5 (2020).
541	13	Polygenic Risk Score Task Force of the International Common Disease, A.
542		Responsible use of polygenic risk scores in the clinic: potential benefits, risks
543		and gaps. Nat Med 27, 1876-1884, doi:10.1038/s41591-021-01549-6 (2021).
544 545	14	Wainschtein, P. <i>et al.</i> Assessing the contribution of rare variants to complex
545 546		trait heritability from whole-genome sequence data. <i>Nat Genet</i> <b>54</b> , 263-273, doi:10.1038/s41588-021-00997-7 (2022).
547	15	Singh, T. et al. Rare coding variants in ten genes confer substantial risk for
548		schizophrenia. Nature 604, 509-516, doi:10.1038/s41586-022-04556-w
549		(2022).
550	16	Backman, J. D. <i>et al.</i> Exome sequencing and analysis of 454,787 UK Biobank
551		participants. Nature 599, 628-634, doi:10.1038/s41586-021-04103-z (2021).
552	17	Sun, B. B. <i>et al.</i> Genetic associations of protein-coding variants in human
553		disease. Nature 603, 95-102, doi:10.1038/s41586-022-04394-w (2022).
554 555	18	Buniello, A. <i>et al.</i> The NHGRI-EBI GWAS Catalog of published
555 556		genome-wide association studies, targeted arrays and summary statistics 2019. <i>Nucleic Acids Res</i> <b>47</b> , D1005-D1012, doi:10.1093/nar/gky1120 (2019).
557	19	Szustakowski, J. D. et al. Advancing human genetics research and drug
558	17	discovery through exome sequencing of the UK Biobank. Nat Genet 53,
559		942-948, doi:10.1038/s41588-021-00885-0 (2021).
560	20	Zhou, W. et al. Scalable generalized linear mixed model for region-based
561		association tests in large biobanks and cohorts. <i>Nat Genet</i> <b>52</b> , 634-639,
562		doi:10.1038/s41588-020-0621-6 (2020).
563	21	Zhou, W. <i>et al.</i> Efficiently controlling for case-control imbalance and sample
564 565		relatedness in large-scale genetic association studies. <i>Nat Genet</i> <b>50</b> , 1335-1341, doi:10.1038/s41588-018-0184-y (2018).
566	22	McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome biology 17,
567		122, doi:10.1186/s13059-016-0974-4 (2016).
568	23	Sauna, Z. E. & Kimchi-Sarfaty, C. Understanding the contribution of
569		synonymous mutations to human disease. Nature reviews. Genetics 12,
570		683-691, doi:10.1038/nrg3051 (2011).
571	24	Shen, X., Song, S., Li, C. & Zhang, J. Synonymous mutations in
572 573		representative yeast genes are mostly strongly non-neutral. <i>Nature</i> , doi:10.1038/s41586-022-04823-w (2022).
515		uol.10.1050/541500-022-04025-w (2022).

574 575 576	25	Wang, Q. <i>et al.</i> Rare variant contribution to human disease in 281,104 UK Biobank exomes. <i>Nature</i> <b>597</b> , 527-532, doi:10.1038/s41586-021-03855-y (2021).
577 578 579	26	Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. <i>Bioinformatics</i> <b>26</b> , 2190-2191, doi:10.1093/bioinformatics/btq340 (2010).
580 581 582	27	Liu, Y. <i>et al.</i> ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing Studies. <i>Am J Hum Genet</i> <b>104</b> , 410-421, doi:10.1016/j.ajhg.2019.01.002 (2019).
583 584 585 586	28	Bhattacharjee, S. <i>et al.</i> A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits. <i>Am J Hum Genet</i> <b>90</b> , 821-835, doi:10.1016/j.ajhg.2012.03.015 (2012).
587 588	29	Vivian, J. <i>et al.</i> Toil enables reproducible, open source, big biomedical data analyses. <i>Nat Biotechnol</i> <b>35</b> , 314-316, doi:10.1038/nbt.3772 (2017).
589 590 591	30	Yu, G., Wang, LG., Han, Y. & He, QY. clusterProfiler: an R package for comparing biological themes among gene clusters. <i>Omics: a journal of integrative biology</i> <b>16</b> , 284-287 (2012).
592 593	31	Satpathy, S. <i>et al.</i> A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> <b>184</b> , 4348-4371 e4340, doi:10.1016/j.cell.2021.07.016 (2021).
594 595 596 597	32	Szklarczyk, D. <i>et al.</i> The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. <i>Nucleic Acids Res</i> <b>49</b> , D605-D612, doi:10.1093/nar/gkaa1074 (2021).
598 599 600	33	Lambert, S. A. <i>et al.</i> The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. <i>Nat Genet</i> <b>53</b> , 420-425, doi:10.1038/s41588-021-00783-5 (2021).
601 602 603	34	Zeng, C. <i>et al.</i> Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. <i>JAMA Oncol</i> , doi:10.1001/jamaoncol.2022.0373 (2022).
604 605 606	35	Cheng, S. <i>et al.</i> Exome-wide screening identifies novel rare risk variants for major depression disorder. <i>Mol Psychiatry</i> , doi:10.1038/s41380-022-01536-4 (2022).
607 608 609	36	Reiner, A. S. <i>et al.</i> Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. <i>J Natl Cancer Inst</i> <b>112</b> , 1275-1279, doi:10.1093/jnci/djaa031 (2020).

24

610 611 612	37	Breyer, J. P. <i>et al.</i> An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. <i>Am J Hum Genet</i> <b>94</b> , 395-404, doi:10.1016/j.ajhg.2014.01.019 (2014).
613 614 615	38	Hayashi, H. <i>et al.</i> The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. <i>Oncogene</i> <b>34</b> , 199-208, doi:10.1038/onc.2013.547 (2015).
616 617 618	39	Cohen, P. & Strickson, S. The role of hybrid ubiquitin chains in the MyD88 and other innate immune signalling pathways. <i>Cell Death Differ</i> <b>24</b> , 1153-1159, doi:10.1038/cdd.2017.17 (2017).
619 620 621	40	Salcedo, R., Cataisson, C., Hasan, U., Yuspa, S. H. & Trinchieri, G. MyD88 and its divergent toll in carcinogenesis. <i>Trends Immunol</i> <b>34</b> , 379-389, doi:10.1016/j.it.2013.03.008 (2013).
622 623 624 625	41	de Groen, R. A. L., Schrader, A. M. R., Kersten, M. J., Pals, S. T. & Vermaat, J. S. P. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. <i>Haematologica</i> <b>104</b> , 2337-2348, doi:10.3324/haematol.2019.227272 (2019).
626 627 628 629	42	Wang, X. <i>et al.</i> ZEB1 activated-VPS9D1-AS1 promotes the tumorigenesis and progression of prostate cancer by sponging miR-4739 to upregulate MEF2D. <i>Biomed Pharmacother</i> <b>122</b> , 109557, doi:10.1016/j.biopha.2019.109557 (2020).
630 631 632	43	Ettinger, D. S. <i>et al.</i> NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. <i>J Natl Compr Canc Netw</i> <b>19</b> , 254-266, doi:10.6004/jnccn.2021.0013 (2021).
633 634 635	44	Kleszczynski, K. <i>et al.</i> Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells. <i>J Pineal Res</i> <b>67</b> , e12610, doi:10.1111/jpi.12610 (2019).
636 637 638	45	Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A. & D'Andrea, A. D. DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discov</i> <b>7</b> , 675-693, doi:10.1158/2159-8290.CD-17-0226 (2017).
639 640 641	46	Cabrera, T., Lopez-Nevot, M. A., Gaforio, J. J., Ruiz-Cabello, F. & Garrido, F. Analysis of HLA expression in human tumor tissues. <i>Cancer Immunol Immunother</i> <b>52</b> , 1-9, doi:10.1007/s00262-002-0332-0 (2003).
642 643 644	47	Lawrence, M. S. <i>et al.</i> Discovery and saturation analysis of cancer genes across 21 tumour types. <i>Nature</i> <b>505</b> , 495-501, doi:10.1038/nature12912 (2014).
645	48	Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic

646 647		mutations in class I HLA genes. <i>Nat Biotechnol</i> <b>33</b> , 1152-1158, doi:10.1038/nbt.3344 (2015).
648 649	49	Karantza, V. Keratins in health and cancer: more than mere epithelial cell markers. <i>Oncogene</i> <b>30</b> , 127-138, doi:10.1038/onc.2010.456 (2011).
650 651	50	Li, J. <i>et al.</i> Molecular biology of BPIFB1 and its advances in disease. <i>Ann Transl Med</i> <b>8</b> , 651, doi:10.21037/atm-20-3462 (2020).
652 653 654	51	Independent, U. K. P. o. B. C. S. The benefits and harms of breast cancer screening: an independent review. <i>Lancet</i> <b>380</b> , 1778-1786, doi:10.1016/S0140-6736(12)61611-0 (2012).
655 656 657 658	52	Jonas, D. E. <i>et al.</i> Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. <i>JAMA</i> <b>325</b> , 971-987, doi:10.1001/jama.2021.0377 (2021).
659 660 661	53	Buskermolen, M. <i>et al.</i> Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. <i>BMJ</i> <b>367</b> , 15383, doi:10.1136/bmj.15383 (2019).
662		

663

# 664 Figure legends

665 Figure 1. (a) Manhattan plot for the single variant association results in ExWAS. The blue dash line indicates the genome-wide significance level ( $P < 5 \times 10^{-8}$ ). (b) 666 667 Manhattan plot for the gene-based association results in ExWAS. The blue dash line indicates the Bonferroni correction level ( $P < 2.5 \times 10^{-6}$ ). (c) The heatmap of 668 669 variant-level and gene-level association results for the genes shared at least two 670 cancer types. We report the signal if it reaches nominal P < 0.05 in the corresponding 671 cancer type (red: odds ratio (OR)>1; blue: OR<1). The grey color indicates 672 association P > 0.05.

Figure 2. (a) Circos plot for the genes identified in the cross-trait meta-analysis. (b) Heatmap for the number of shared genetic variants across each cancer pair. The red color indicates the shared variants with one-directional effects. The blue color indicates the shared variants with bidirectional effects between the cancer pairs.

677 Figure 3. (a) Heatmap of fold change (FC) values to compare gene expression 678 between TCGA tumor tissues and GTEx healthy normal tissues. (b) Volcano plot for 679 the FC values and -log(P) values for comparison of gene expression. (c) Heatmap of 680 FC values to compare protein abundance between CPTAC tumor tissues and adjacent 681 normal tissues. NA: not available. (d) Volcano plot for the FC values and  $-\log(P)$ 682 values for comparison of protein abundance. (e) KEGG pathway network from the 683 enrichment analysis of the pleiotropic genes. (f) Protein-protein interaction network of 684 the signal genes and pleiotropic genes.

Figure 4. Cumulative cancer incidence plot for the 20 cancer types in the replication
set (WES-150k). The red line indicates the extremely high-risk persons, the green line
indicates the high-risk population, and the blue line indicates the low-risk persons.
The *P* values were calculated using the log-rank tests.

**Figure 5.** (a) The dot plot of the hazard ratios (HRs) and 95% confidence intervals (CIs) of exome-wide risk scores (ERS). The low-risk subgroup (blue dot) was set as the reference group. The red dot indicates the extremely high-risk persons, the green dot indicates the high-risk population. (b) The dot plot of the HRs and 95% CIs of polygenic risk scores (PRS) for 17 cancer types, while liver, stomach, and sarcoma cancers did not have reported PRSs. (c) The C-index values of ERS and PRS generated by the Cox regression model.


# 696 Supplementary Figures


- 697 Figure S1. Q-Q plots of single variant tests for each cancer
- 698 Figure S2. Q-Q plot combining all the P values of pan-cancer
- 699 Figure S3. Manhattan plot for the single variant analyses of each cancer
- Figure S4. Cumulative cancer incidence plot for the 20 cancer types in the wholeUKB-450k population.
- Figure S5. Histogram of the exome-wide risk scores (ERS) in each cancer
- Figure S6. Density plot of the exome-wide risk scores (ERS) in cases and controls


## 704 Supplementary Tables

- 705 Table S1. Demographic characteristics in the UK Biobank cohort
- Table S2. Association results for independent single variants with  $P < 5 \times 10^{-8}$  in the
- 707 whole UKB-450k population
- Table S3. Association results for single variants with  $P < 5 \times 10^{-8}$  in at least two cancer types
- Table S4. Association results for genes with  $P<2.5\times10^{-6}$  in the whole UKB-450k population


- Table S5. Association results for genes with  $P<2.5\times10^{-6}$  in at least two cancer types
- 713 Table S6. Cross-trait meta-analysis results for single variants with one-directional714 effects
- 715 Table S7. Cross-trait meta-analysis results for single variants with bidirectional effects
- 716 Table S8. Number of independent shared genetic variants in the cross-trait717 meta-analysis
- Table S9. KEGG enrichment analysis for the genes identified in cross-traitmeta-analysis
- Table S10. Model parameters for the exome-wide risk scores (ERS) in 20 cancer types
- 721 Table S11. Correlation analysis for ERS and PRS
- Table S12. Number of tissues included in the comparison analyses for geneexpression in tumor and healthy normal tissues
- Table S13. Number of tissues included in the comparison analyses for proteinabundance in CPTAC
- Table S14. Information of the selected polygenic risk score (PRS) in PGS catalog
- 727









# one-directional SNV







Cancer type

Cancer type